___

• 1. Gimble JM. Adipose tissue-derived therapeutics. Expert Opin Biol Ther, 2003; 3:705-13.
• 2. Chen XD, Lei T, Xia T, Gan L, Yang ZQ. Increased expression of resistin and tumour necrosis factor-alpha in pig adipose tissue as well as effect of feeding treatment on resistin and cAMP pathway. Diabetes Obes Metab, 2004;6:271-79.
• 3. Wisse BE, Ogimoto K, Morton GJ et al. Physiological Regulation of Hypothalamic Interleukin-1beta (IL-1{beta}) Expression by Leptin and Glucocorticoids: Implications for Energy Homeostasis. Am J Physiol Endocrinol Metab, 2004;287:1107-13.
• 4. Deplanque D. [Cell protection through PPAR nuclear receptor activation]. Therapie, 2004;59:25-29.
• 5. Steffes MW, Gross MD, Schreiner PJ, et al. Serum adiponectin in young adultsinteractions with central adiposity,circulating levels of glucose, and insulin resistance: the CARDIA study. Ann Epidemiol, 2004;14:492-98.
• 6. Looker HC, Krakoff J, Funahashi T, et al. Adiponectin concentrations are influenced by renal function and diabetes duration in pima indians with type 2 diabetes. J Clin Endocrinol Metab, 2004;89:4010-17.
• 7. Raji A, Gerhard-Herman MD, Warren M et al. Insulin resistance and vascular dysfunction in nondiabetic asian indians. J Clin Endocrinol Metab, 2004;89:3965-72.
• 8. Masaki T, Chiba S, Tatsukawa H, et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology. 2004; 40:177-84.
• 9. Chinetti G, Zawadski C, Fruchart JC, Staels B. Expression of adiponectin receptors in human macrophages and regulation by agonists of the nuclear receptors PPARalpha, PPARgamma, and LXR. Biochem Biophys Res Commun. 2004;314:151-58.
• 10. Peelman F, Waelput W, Iserentant H, et al. Leptin: linking adipocyte metabolism with cardiovascular and autoimmune diseases. Prog Lipid Res. 2004;43:283-301.
• 11. Gaja A, Chury Z, Pecen L, et al. Bone marrow and peripheral blood leptin levels in lymphoproliferative diseases--relation to the bone marrow fat and infiltration. Neoplasma. 2000;47:307-12.
• 12. Fajas L, Annicotte JS, Miard S, et al. Impaired pancreatic growth, beta cell mass, and beta cell function in E2F1 (-/-)mice. J Clin Invest, 2004;113:1288-95.
• 13. Martinez-Carpio PA, Fiol C, Hurtado I, et al. Relation between leptin and body fat distribution in menopausal status. J Physiol Biochem, 2003;59:301-07.
• 14. Tremblay A, Pelletier C, Doucet E, Imbeault P. Thermogenesis and weight loss in obese individuals: a primary association with organochlorine pollution. Int J Obes Relat Metab Disord. 2004;28:936-39.
• 15. Klaus S. Adipose tissue as a regulator of energy balance. Curr Drug Targets. 2004;5:241-50.
• 16. Cancello R, Tounian A, Poitou Ch, Clement K. Adiposity signals, genetic and body weight regulation in humans. Diabetes Metab, 2004;30:215-27.
• 17. Sun C, Yu X, Li Y, Liu R. Effects of dietary calcium on the blood glucose, blood lipid and hormone of rat fed a high fat diet Wei Sheng Yan Jiu. 2004;33:164-76.
• 18. Soderberg S, Stegmayr B, Stenlund H, et al. Leptin, but not adiponectin, predicts stroke in males. J Intern Med. 2004 Aug;256(2):128-36.
• 19. Ma XH, Wang WM. The study of leptin resistance and insulin resistance in subjects with nonalcoholic fatty liver. Zhonghua Gan Zang Bing Za Zhi. 2004;12:651-55.
• 20. Swain JE, Dunn RL, McConnell D, Gonzalez-Martinez J, Smith GD. Direct Effects of Leptin on Mouse Reproductive Function: Regulation of Follicular, Oocyte and Embryo Development. Biol Reprod, 2004;71:1446-52.
• 21. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab, 2003;88:5452-55.
• 22. Delporte ML, Ait El Mkadem S, Quisquater M, Brichard SM. Leptin treatment markedly increased plasma adiponectin, but barely decreased plasma resistin of ob/ob mice. Am J Physiol Endocrinol Metab, 2004; 287:446-53.
• 23. Das UN. GLUT-4, tumour necrosis factor, essential fatty acids and daf-genes and their role in glucose homeostasis, insulin resistance, non-insulin dependent diabetes mellitus, and longevity. J Assoc Physicians India. 1999;47:431-35.
• 24. Ryden M, Arvidsson E, Blomqvist L, et al. Targets for TNF-alpha-induced lipolysis in human adipocytes. Biochem Biophys Res Commun. 2004;318:168-75.
• 25. Wellen KE, Uysal KT, Wiesbrock S, et al. Interaction of tumor necrosis factor-alphaand thiazolidinedione-regulated pathways in obesity. Endocrinology, 2004;145:2214-20.
• 26. Cariou B, Capitaine N, Le Marcis V, et al. Increased adipose tissue expression of Grb14 in several models of insulin resistance. FASEB J. 2004;18:965-67.
• 27. Pang XP, Yoshimura M, Hershman JM. Suppression of rat thyrotroph and thyroid cell function by tumor necrosis factor-alpha. Thyroid. 1993;3:325-30.
• 28. Elsasser TH, Caperna TJ, Fayer R. Tumor necrosis factor-alpha affects growth hormone secretion by a direct pituitary interaction. Proc Soc Exp Biol Med, 1991;198:547-54.
• 29. Warne JP. Tumour necrosis factor alpha: a key regulator of adipose tissue mass. J Endocrinol. 2003;177:351-55.
• 30. Chan JC, Cheung JC, Stehouwer CD, et al. The central roles of obesity-associated dyslipidaemia, endothelial activation and cytokines in the Metabolic Syndrome--an analysis by structural equation modelling. Int J Obes Relat Metab Disord, 2002;26:994-1008.
• 31. de Maat MP, Pietersma A, Kofflard M, Sluiter W, Kluft C. Association of plasma fibrinogen levels with coronary artery disease, smoking and inflammatory markers. Atherosclerosis, 1996;121:185-91.
• 32. Piconi L, Quagliaro L, Da Ros R, et al. Intermittent high glucose enhances ICAM-1, VCAM-1, E-selectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. J Thromb Haemost, 2004;2:1453-59.
• 33. Wallenius V, Wallenius K, Ahren B, et al. Interleukin-6-deficient mice develop mature-onset obesity. Nat Med. 2002;8:75-79.
• 34. Spangelo BL, Judd AM, Isakson PC, MacLeod RM. Interleukin-6 stimulates anterior pituitary hormone release in vitro. Endocrinology, 1989;125:575-77.
• 35. Samdal F, Mollnes TE, Amland PF, Truedsson L. Modest release of adipsin/factor D by liposuction when using the superwet or tumescent technique. Plast Reconstr Surg. 1997;99:1591-4
• 36. Rato Q, Cianflone K, Sniderman A. [Adipsin system--acylation-stimulation protein (ASP) and hyperapo-B] Rev Port Cardiol, 1996;15:433-38.
• 37. Martin LJ, Cianflone K, Zakarian R, et al. Bivariate linkage between acylationstimulating protein and BMI and high-density lipoproteins. Obes Res. 2004;12:669-78
• 38. Maslowska M, Vu H, Phelis S, et al. Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations. Eur J Clin Invest, 1999;29:679-86.
• 39. Spiegelman BM, Lowell B, Napolitano A, et al. Adrenal glucocorticoids regulate adipsin gene expression in genetically obese mice. J Biol Chem, 1989;264:1811-15.
• 40. Cianflone K, Zhang XJ, Genest J Jr, Sniderman A. Plasma acylation-stimulating protein in coronary artery disease. Arterioscler Thromb Vasc Biol, 1997;17:1239-44.
• 41. Germinario R, Sniderman AD, Manuel S, et al. Coordinate regulation of triacylglycerol synthesis and glucose transport by acylation-stimulating protein. Metabolism. 1993;42:574-80.
• 42. Matsuda M, Ouchi N, Kihara S, et al. Genomic structure and insulin-mediated repression of the aquaporin adipose (AQPap), adipose-specific glycerol channel. J Biol Chem, 2001;276:36251-60.
• 43. Kishida K, Kuriyama H, Funahashi T, et al. Aquaporin adipose, a putative glycerol channel in adipocytes. J Biol Chem. 2000;275:20896-902.
• 44. He G, Pedersen SB, Bruun JM, et al. Differences in plasminogen activator inhibitor 1 in subcutaneous versus omental adipose tissue in non-obese and obese subjects. Horm Metab Res. 2003;35:178-82.
• 45. Alessi MC, Juhan-Vague I. Contribution of PAI-1 in cardiovascular pathology. Arch Mal Coeur Vaiss, 2004; 97:673-78.
• 46. Caballero AE, Delgado A, Aguilar- Salinas CA, et al. The differential effects of metformin on markers of endothelial activation and inflammation in subjects with impaired glucose tolerance: a placebo-controlled, randomized clinical trial. J Clin Endocrinol Metab, 2004;89:3943-48.
• 47. Oishi K, Ohkura N, Kasamatsu M, et al. Tissue-specific augmentation of circadian PAI-1 expression in mice with streptozotocininduced diabetes. Thromb Res, 2004;114:129-35.
• 48. Engeli S, Schling P, Gorzelniak K, et al. The adipose-tissue renin-angiotensinaldosterone system: role in the metabolic syndrome? Int J Biochem Cell Biol, 2003;35:807-25.
• 49. Serazin V, Dieudonne MN, Morot M, de Mazancourt P, Giudicelli Y. cAMP-positive regulation of angiotensinogen yine expression and protein secretion in rat adipose tissue. Am J Physiol Endocrinol Metab, 2004;286:434-38.
• 50. Buus NH, Bottcher M, Jorgensen CG, et al. Myocardial Perfusion During Long-Term Angiotensin-Converting Enzyme Inhibition or {beta}-Blockade in Patients With Essential Hypertension. Hypertension, 2004;44:465-70.
• 51. Giacchetti G, Faloia E, Sardu C, et al. Gene expression of angiotensinogen in adipose tissue of obese patients. Int J Obes Relat Metab Disord. 2000;24:142-43.
• 52. Taylor DM, Minotti S, Agar JN, Durham HD. Overexpression of Metallothionein Protects Cultured Motor Neurons Against Oxidative Stress, but not Mutant Cu/Zn-Superoxide Dismutase Toxicity. Neurotoxicology. 2004;25:779-92.
• 53. Tomita K, Azuma T, Kitamura N, et al. Leptin deficiency enhances sensitivity of rats to alcoholic steatohepatitis through suppression of metallothionein. Am J Physiol Gastrointest Liver Physiol. 2004;287:1078-85.
• 54. Mandard S, Zandbergen F, Tan NS, et al. The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment. J Biol Chem. 2004;279:34411-20.
• 55. Fruhbeck G. The adipose tissue as a source of vasoactive factors. Curr Med Chem Cardiovasc Hematol Agents, 2004;2:197-208.